This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Rebat M. Halder, MD; Eliot F. Battle, MD; Elaine M. Smith, MD
Department of Dermatology Howard University Hospital 2041 Georgia Ave NW Washington, DC 20060

Arch Dermatol. 1995;131(6):734-735.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Vitiligo is an acquired, sometimes familial, depigmentation disorder of the skin and hair. Oral or topical psoralen photochemotherapy (PUVA) is the most popular and efficacious treatment currently available in the United States for repigmentation of vitiliginous patches.¹ However, the long-term safety of this treatment is still under investigation, and further studies are warranted.

There are limited published studies examining the long-term risk in patients with vitiligo who have been treated with oral PUVA therapy. We found no published studies examining the long-term risk in patients with vitiligo treated with topical PUVA therapy. A study of 59 patients with vitiligo, who received oral PUVA therapy from 1972 through 1986, reported no incidence of skin cancers, actinic keratoses, or lentigines.² Likewise, a 1984 study examining 596 East Indian patients with vitiligo, who were treated with oral psoralen and sunlight (PUVASOL), reported that no increased risk of cutaneous carcinoma was apparent . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?